- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Inactivation.
Displaying page 1 of 2.
EudraCT Number: 2011-004139-29 | Sponsor Protocol Number: RETIC | Start Date*: 2011-12-06 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck / UK für Anästhesie und Intensivmedizin & UK für Allgem. u. Chirurg. Intensivmedizin | |||||||||||||
Full Title: RETIC trial: Reversal of Trauma Induced Coagulopathy by using Coagulation factor concentrates or Fresh frozen Plasma | |||||||||||||
Medical condition: Major trauma (Injury Severity Score, ISS >15), clinical signs/risk of blood loss and coagulopathy as measured by rotational thrombelastometry (ROTEM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024263-40 | Sponsor Protocol Number: PEx in DIC Version 1 | Start Date*: 2011-09-08 |
Sponsor Name:Medizinische Universität Wien, Univ. Klinik f. Klinische Pharmakologie | ||
Full Title: Plasma exchange as therapy for disseminated intrevascular coagulation (DIC)- a randomized-controlled trial | ||
Medical condition: Disseminated intravascular coagulation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-003517-17 | Sponsor Protocol Number: ALL2518 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
Full Title: Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL). | |||||||||||||
Medical condition: Adult patients, aged between 18 and 65, diagnosed with Acute Ph Lymphoblastic Leukemia negative (LAL Ph-) untreated, with a favorable impact on the prognosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002117-30 | Sponsor Protocol Number: 000010/BT | Start Date*: 2016-02-16 | |||||||||||
Sponsor Name:Bone Therapeutics S.A. | |||||||||||||
Full Title: A Two-stage 6-month, Multicentre, Randomised, Double-blind, Controlled Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Patients with Symptomatic Knee Osteo... | |||||||||||||
Medical condition: Symptomatic osteoarthritis of the knee with Kellgren-Lawrence grade II and III | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000067-25 | Sponsor Protocol Number: ALL11 | Start Date*: 2012-10-19 | |||||||||||
Sponsor Name:Princess Máxima Center for pediatric oncology | |||||||||||||
Full Title: Protocol ALL-11: Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia | |||||||||||||
Medical condition: Acute lymphoblastic leukemia in children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005174-23 | Sponsor Protocol Number: CAVA2Dec04 | Start Date*: 2005-04-11 |
Sponsor Name:NHS Grampian | ||
Full Title: Is smooth muscle mitogenesis down regulated by platelet inactivation with combination antiplatelet therapy after angioplasty for claudication? | ||
Medical condition: Intermittent claudication = stenosis of superficial femoral artery requiring percutaneous angioplasty | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004164-23 | Sponsor Protocol Number: 710501 | Start Date*: 2006-01-09 |
Sponsor Name:Baxter AG | ||
Full Title: Single-blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero cell derived) with a Licensed Egg derived Infl... | ||
Medical condition: Influenza Vaccination in healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002127-26 | Sponsor Protocol Number: BAFFI_14 | Start Date*: 2015-10-13 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: Randomized, single-blind, controlled study of the anti-BAFF antibody belimumab or methylprednisolone treatment in hyperthyroid Graves' disease (GD) and active orbitopathy (GO) | |||||||||||||
Medical condition: GRAVES' ORBITOPATHY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002790-22 | Sponsor Protocol Number: ML39921 | Start Date*: 2019-04-11 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | ||||||||||||||||||
Full Title: Tocilizumab in Graves’ Orbitopathy (TOGO). Multicenter, randomized, observer-blind, controlled study of the anti-IL-6 receptor antibody tocilizumab (TCZ) or methylprednisolone (MP) treatment in pat... | ||||||||||||||||||
Medical condition: Active moderate-severe Graves' Orbitopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003042-20 | Sponsor Protocol Number: ET21-169 | Start Date*: 2022-06-21 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: PARPi-PANC - A multicentric, single arm, phase II trial assessing the efficacy of niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer | ||
Medical condition: Patients with metastatic homologous repair-deficient pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004451-70 | Sponsor Protocol Number: NOR-GRASPALL-2016 | Start Date*: 2017-04-06 |
Sponsor Name:Department of pediatrics, Aarhus University Hospital | ||
Full Title: NOR-GRASPALL 2016: SINGLE-ARM PHARMACOKINETIC/PHARMACODYNAMIC AND SAFETY STUDY OF ERYASPASE (GRASPA®) FOR PATIENTS WITH HYPERSENSITIVITY TO PEG-ASPARAGINASE, DIAGNOSED WITH PH(-) ACUTE LYMPHOBLASTI... | ||
Medical condition: Patients with acute lymphoblastic leukemia with allergy against PEG-asparaginase | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) NO (Completed) FI (Completed) SE (Completed) EE (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000707-81 | Sponsor Protocol Number: VIPER-SEPSIS | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | |||||||||||||
Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SEPSIS) trial | |||||||||||||
Medical condition: Patients with septic shock admitted to the intensive care unit | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001060-11 | Sponsor Protocol Number: FSJD-RTB-2015 | Start Date*: 2017-08-03 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma | |||||||||||||
Medical condition: Refractory Retinoblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001196-20 | Sponsor Protocol Number: H2013 | Start Date*: 2013-09-24 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO MILANO | |||||||||||||
Full Title: PROSPECTIVE STUDY ON THE EFFECTIVENESS OF TWO DIFFERENT DOSES OF INTRAVENOUS METHYLPREDNISOLONE IN THE TREATMENT OF ACUTE DYSTHYROID OPTIC NEUROPATHY | |||||||||||||
Medical condition: GRAVES' ORBITOPATHY | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000427-27 | Sponsor Protocol Number: VIPER-SHOCK | Start Date*: 2017-03-30 | |||||||||||
Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | |||||||||||||
Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SHOCK) trial | |||||||||||||
Medical condition: Patients with septic shock admitted to the intensive care unit. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005486-14 | Sponsor Protocol Number: EPIC-19 | Start Date*: 2021-01-11 |
Sponsor Name:Wroclaw Medical University | ||
Full Title: Using of convalescent plasma in the treatment of COVID-19 patients with metabolomic and laboratory evaluation of the progress of plasma therapy | ||
Medical condition: Covid-19 (Coronavirus Disease 2019) – acute infectious disease of the respiratory system caused by SARS-CoV-2 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-007740-10 | Sponsor Protocol Number: TAM-01 | Start Date*: 2008-01-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA | |||||||||||||
Full Title: Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN) | |||||||||||||
Medical condition: chemoprevention of breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001240-25 | Sponsor Protocol Number: MOURO48 | Start Date*: Information not available in EudraCT |
Sponsor Name:Radboudumc | ||
Full Title: Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer | ||
Medical condition: (metastatic) castration-resistant prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005156-34 | Sponsor Protocol Number: UCL/11/0353 | Start Date*: 2012-08-09 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenstrőm macroglobulinaemia: a randomised phase II s... | |||||||||||||
Medical condition: Waldenstrom's macroglobulinaemia (WM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000814-23 | Sponsor Protocol Number: CLDK378A2407 | Start Date*: 2015-10-26 |
Sponsor Name:Novartis Farmacéutica, S.A. | ||
Full Title: A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphom... | ||
Medical condition: Advanced solid tumors and hematological malignancies with ALK genetic alteration and/or overexpression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Temporarily Halted) CZ (Completed) FR (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
